Desk›Healthcare› Marksans Pharma Ltd
Marksans Pharma Ltd
BSE 524404 · NSE MARKSANS · ISIN INE750C01026 · Group A · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹326.05
-1.48%
BSE close, 28 August 2026
₹14,775.40 cr
45.3 cr shares · Small cap
₹6,981.70 cr
as published
45.9× · 11.44×
EPS ₹7.10 · BV ₹28.50
1,341.48 / 300.70
₹ cr, as filed
23
5 selected · 22%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -5.7% |
|---|---|
| Against 52-week low | +109.0% |
| Day change | -1.48% |
| Size band | Small cap |
| Index membership | None |
Valuation as published by BSE
| Earnings per share | ₹7.10 |
|---|---|
| Price / earnings | 45.92× |
| Price / book | 11.44× |
| Book value — derived, price ÷ P/B | ₹28.50 |
| Return on equity | 24.92% |
| Operating margin | 31.00% |
| Net margin | 21.49% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 24.91%
- ROE as published
- 24.92%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 321.19 | 69.04 | 1.52 | 31.00% | 21.49% |
| Mar-26 · Q | 361.57 | 91.92 | 2.03 | 36.91% | 25.42% |
| FY25-26 | 1,341.48 | 300.70 | 6.64 | 31.84% | 22.42% |
Quarter on quarter
- Revenue, quarter on quarter
- -11.2%
- Net profit, quarter on quarter
- -24.9%
- Operating margin, quarter on quarter
- -591 bps
Disclosure profile 23 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Board Outcome | 1 |
| Concall Transcript | 1 |
| Investor Presentation | 1 |
| Press Release | 1 |
| Results | 1 |
| Selected sub-total | 5 |
| Procedural | |
| General | 4 |
| Newspaper Publication | 4 |
| AGM / EGM | 3 |
| Analyst / Investor Meet | 3 |
| Annual Report | 1 |
| BRSR | 1 |
| Board Meeting | 1 |
| Trading Window | 1 |
| Procedural sub-total | 18 |
| Total | 23 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group A, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
23 filings · 5 selected · busiest 2026-08-12
Filing rhythm · the twelve most recent
2026-08-122026-09-25
SelectedProcedural
Filings
23 in the window · 16 earlier on record
-
25 September 2026 ·
Closure of Trading Window
Intimation of Closure of Trading Window for the quarter and half year ended 30 September, 2026
Insider Trading / SAST / Closure of Trading Window View filing →
-
17 September 2026 ·
Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares
Notice to Shareholders regarding re-opening of Special Window for Re-lodgement of transfer requests of Physical Shares
Company Update / General View filing →
-
7 September 2026 ·
Newspaper Publication
Copy of Newspaper Publication regarding transfer of unclaimed dividend and equity shares of the Company to the IEPF
Company Update / Newspaper Publication View filing →
-
1 September 2026 ·
Analyst / Investor Meet - Intimation
Intimation of schedule of Investors Meet
Company Update / Analyst / Investor Meet View filing →
-
27 August 2026 ·
Voting Results Of The 34Th Annual General Meeting Of The Company
Please find attached the voting result of the 34th AGM
Company Update / General View filing →
-
27 August 2026 ·
Shareholder Meeting / Postal Ballot-Scrutinizer's Report
Scrutinizer's Report along with voting result for the 34th AGM
AGM/EGM / AGM View filing →
-
27 August 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceeding of 34th Annual General Meeting of the Company held today
AGM/EGM / AGM View filing →
-
26 August 2026 ·
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Please find attached disclosure on ESG rating
Company Update / General View filing →
-
20 August 2026 ·
Earnings Call Transcript
Transcript of Investors/Analyst meet on Q1 FY 27 Financial Results
Company Update / Earnings Call Transcript View filing →
-
13 August 2026 ·
Analyst / Investor Meet - Outcome
Audio Recording of investor(s)/analyst(s) meet Conference Call on Q1 FY 27 Financial Results
Company Update / Analyst / Investor Meet View filing →
-
13 August 2026 ·
Newspaper Publication
Newspaper Publication for Unaudited Financial Results for the quarter ended June 30, 2026
Company Update / Newspaper Publication View filing →
-
12 August 2026 ·
Press Release / Media Release
Press Release for Financial Results Q1 FY 27
Company Update / Press Release / Media Release View filing →
-
12 August 2026 ·
Investor Presentation
Investor Presentation Q1 FY 27
Company Update / Investor Presentation View filing →
-
12 August 2026 ·
Result For The Quarter Ended June 30, 2026
The Board in its meeting held on 12 August 2026 approved Financial Results for the quarter ended June 30, 2026
Result / Financial Results View filing →
-
12 August 2026 ·
Board Meeting Outcome for Outcome Of Board Meeting Held On 12 August 2026
The Board in its meeting held on 12 August 2026 approved the Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter ended June 30, 2026
Board Meeting / Outcome of Board Meeting View filing →
-
6 August 2026 ·
Newspaper Publication
Please find attached newspaper publication for Annual General Meeting Notice
Company Update / Newspaper Publication View filing →
-
4 August 2026 ·
Business Responsibility and Sustainability Reporting (BRSR)
Please find enclosed the BRSR
Others / Business Responsibility and Sustainability Reporting (BRSR) View filing →
-
4 August 2026 ·
Reg. 34 (1) Annual Report.
Please find attached herewith the Annual Report for the Financial Year 2025-26
Others / Reg. 34 (1) Annual Report View filing →
-
4 August 2026 ·
Shareholders Annual General Meeting To Be Held On August 27, 2026
Notice of the 34th Annual General Meeting of the Company proposed to be held on 27 August 2026
AGM/EGM / AGM View filing →
-
3 August 2026 ·
Analyst / Investor Meet - Intimation
Intimation of schedule for Q1FY27 Earnings Conference Call
Company Update / Analyst / Investor Meet View filing →
-
31 July 2026 ·
Board Meeting Intimation for Board Meeting Intimation For Declaration Of Quarterly Results For The Quarter Ended June 30, 2026
Marksans Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve Quarterly Results For The Quarter ....
Board Meeting / Board Meeting View filing →
-
30 July 2026 ·
Newspaper Publication
Newspaper Publication for AGM Intimation
Company Update / Newspaper Publication View filing →
-
20 July 2026 ·
Updates
Update on acquisition of 100 percent share capital of ABCnow GmbH.
Company Update / General View filing →
RSS feed for Marksans Pharma Ltd · the 50 most recent filings